Dr. Mark Fisher received his BS degree in Chemistry from Purdue in 1982, a Ph.D. in Biochemistry from the University of Illinois in 1987 under Dr. Stephen Sligar where he examined how cytochrome P450s biophysically controlled drug clearance rates. He subsequently became a Postdoctoral fellow at NIH under Dr. Earl Stadtman until 1992 where he was among the pioneers in research related to understanding how molecular chaperones controlled protein folding in the cell. He joined the Biochemistry department at the University of Kansas Medical Center in 1992 and is currently a full Professor. His current research focus is centered on developing broad based technologies to identify potential drug candidates that can ameliorate protein folding diseases and can prevent bacterial toxin protein refolding during early stages of bacterial infections. In the latter instance, Dr. Fisher’s laboratory has pioneered efforts to understand and prevent protein structural refolding transformations that occur during early stages of anthrax infections.